Melbourne Haematology

Assoc. Prof Kylie Mason consults at: RMH - Parkville

Suite 11, Level 3,
Private Medical Centre
The Royal Melbourne Hospital
Royal Parade
Parkville VIC 3050
Tel: 03 9968 0011
Fax: 03 9969 0011

View Map of Room's Location

MBBS PhD FRACP FRCPA

• Clinical and Laboratory Haematologist

After graduating from Medicine at the University of Melbourne, Kylie undertook specialist haematology training in Melbourne and is a fellow of both the Royal Australian College of Physicians (FRACP) and the Royal College of Pathologists of Australia (FRCPA).

Kylie was inspired to complete a Ph.D. at the Walter and Eliza Hall Institute of Medical Research /University of Melbourne 2007 focusing on new drugs for leukaemia and lymphoma and the biology of platelets. Kylie continues her research as the Victorian Cancer Agency Fellow at WEHI.

Her work has been published in prestigious international journals and recognized by awards including the Premiers Award for Medical Research in 2009 and the L’Oreal for Women in Science Award in 2012.

Kylie has an appointment as a Clinical Haematologist at the Royal Melbourne Hospital and currently looks after patients with all aspects of both malignant and benign haematological disorders. In particular her main interests are Leukaemia (including CLL / CML and acute leukaemias), Lymphoma, Myeloma, Haemoglobinopathies and disorders of Iron metabolism and blood clotting / platelets.

Kylie has an active interest in clinical trials and in particular translational research relating to her dual role at WEHI / RMH. These include both phase II and phase III clinical trials in leukaemia and lymphoma. Kylie is also actively involved in clinical trial development through the ALLG.

Currently Kylie sees and treats patients at the Royal Melbourne Hospital private consulting rooms.

Kylie has an interest in all aspects of haematology, including Leukaemia (including CLL / CML and acute leukaemias), Lymphoma, Myeloma, Haemoglobinopathies and disorders of Iron metabolism and blood clotting / platelets.

Qualifications

• 2012 NIH Clinical Research Training Course
• 2009 Specialist Certificate in Clinical Research (Oncology)
  First Class Honours, The University of Melbourne
• 2007 Doctor of Philosophy (Medical Biology)
  Thesis entitled 'Investigations into the regulation and modulation of apoptosis in haematological malignancy'
  The University of Melbourne / Walter & Eliza Hall Institute of Medical Research
• 2004 Fellow - Royal Australasian College of Physicians
• 2004 Fellow - Royal College of Pathologists of Australasia
• 1996 Bachelor of Medicine and Bachelor of Surgery

Awards

• 2012 L'Oreal Australia For Women In Science Fellowship - Winner
• 2011 L'Oreal Australia For Women In Science Fellowship - Highly commended
• 2009 Named in 'Melbourne's Top 100 Most Influential People' – The Age
• 2009 Premier's Award for Health and Medical Research, Victorian State Government
• 2008 Young Tall Poppy Science Award, Victorian State Government
• 2007 Student Seminar prize, Walter & Eliza Hall Institute of Medical Research
• 2006 Cleveland Young Investigator's Award, Royal Melbourne Hospital
• 2006 Albert Baikie Memorial Medal – Haematology Society Australia & New Zealand

Professional Memberships

• Victoria Cooperative Oncology Group: Haemato-oncology committee (2012 - present)
• Victorian Comprehensive Cancer Centre Emergency Admissions Committee (2011-present)
• Australian Leukaemia Lymphoma Group (2010-present)
• International Society of Experimental Hematology (2007 – present)
• Melbourne Health Human Ethics Expert Scientific Review Panel (2010 – present)
• Victorian Cancer Agency Early Careers Innovators Network (2007 – 2008)
• American Society of Hematology (2004 – present)
• Haematology Society of Australia and New Zealand (2001 – present)

Selected Publications - Top 10 (All original studies)

1. James E. Vince, W. Wei-Lynn Wong, Ian Gentle, Ramanjaneyulu Allam, Lorraine O’Reilly, Kylie D Mason, Olaf Gross, Greta Guarda, Rosa Castillo, Georg Hacker, John Silke and Jurg Tschopp. Inhibitor of apoptosis (IAP) proteins regulate IL-1 activation. Immunity 2012, 36 (2), 215-227 (impact factor 24.22)
2. Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie D, Grigg AP, Seymour JF, Szer J, Huang DCS, Roberts AW; The BH3 mimetic compound ABT-737 Synergizes with a Range of Cytotoxic Chemotherapy Agents in Chronic Lymphocytic Leukemia. Leukemia, 2009; 23(11): 2034-41
3. Kylie D. Mason, Cassandra J. Vandenberg, Clare L. Scott, Andrew H. Wei, Suzanne Cory, David C.S. Huang, Andrew Roberts; In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. PNAS 2008; 105(46): 17961-6.
4. Mason KD, Juneja SK; Go with the flow for monitoring response in myeloma patients with minimal residual disease. Leukemia and Lymphoma, Feb 2008; 49(2): 117-8.
5. Mason KD, Juneja SK; The value and limitations of immunophenotyping in Acute Myeloid Leukaemia. Educational supplement RCPA Quality Assurance Program. May 2007
6. Mason KD, Carpinelli M, Fletcher J, Collinge J, Hilton A, Ellis S, Kelly P, Ekert P, Metcalf D, Roberts AW, Huang DCS, Kile BT ; Programmed anuclear cell death delimits platelet life span. Cell, 2007; 128, 1173-1186. Cited as ‘Exceptional’ by Faculties of 1000 in Medicine and Biology.
7. van Delft M, Wei A, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis S, Scott CL, Day C, Cory S, Adams J, Roberts AW, Huang DCS; The BH3 mimetic ABT-737 targets selective Bcl‑2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 2006; 10 (5) 389-399. Cited as ‘Must Read’ by Faculties of 1000 in Biology.
8. Mason KD, Juneja SJ, Szer J; The immunophenotype of Acute Myeloid Leukaemia: Is there a relationship to prognosis? Blood Reviews, 2006 (20) 71-82.
9. Mason KD, Szer J; Investigating patients with Macrocytosis. Medicine Today, 2005 6(12) 35-39.
10. Mason KD, Juneja S; Spontaneous rupture of the spleen in the blastic variant of mantle cell lymphoma. Journal of Clinical and Laboratory Haematology, 2003, 25(4), 263-265.